Literature DB >> 8233718

Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis.

T P Dean1, Y Dai, J K Shute, M K Church, J O Warner.   

Abstract

Concurrent pulmonary inflammation and neutrophil infiltration are characteristic of children with cystic fibrosis (CF). The production of the major neutrophil chemotactic cytokine IL-8 by alveolar macrophages or other cells could be of great importance in the pathology of acute lung disease, but its role in the persistent lung inflammation characteristic of CF has not been evaluated. In this study, we have measured, by ELISA, the concentration of IL-8 in sputum, bronchoalveolar lavage, and sera specimens obtained from children with CF. For comparison, IL-8 in bronchoalveolar lavage obtained from asthmatic patients and from non-CF children with or without lung infection and in sera from age-matched controls was measured. High levels of IL-8 were measured in sputum (mean = 2952 pM) and in bronchoalveolar lavage (mean = 6624 pM) from CF patients. In both cases, there was a significant correlation between clinical status (Schwachman score) and IL-8 levels. This was not true for IL-8 levels measured in sera, which nevertheless were significantly higher in CF patients (p = 0.0001) than in normal controls in the over-10-y age group.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8233718     DOI: 10.1203/00006450-199308000-00010

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  49 in total

1.  Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8.

Authors:  Sharmistha Bhattacharyya; Nagaraja S Balakathiresan; Clifton Dalgard; Usha Gutti; David Armistead; Cathy Jozwik; Meera Srivastava; Harvey B Pollard; Roopa Biswas
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 3.  Role of corticosteroids in cystic fibrosis lung disease.

Authors:  I M Balfour-Lynn; R Dinwiddie
Journal:  J R Soc Med       Date:  1996       Impact factor: 5.344

Review 4.  MicroRNA-155: A Master Regulator of Inflammation.

Authors:  Guruswamy Mahesh; Roopa Biswas
Journal:  J Interferon Cytokine Res       Date:  2019-03-20       Impact factor: 2.607

5.  Interleukin-8 production by human airway epithelial cells in response to Pseudomonas aeruginosa clinical isolates expressing type a or type b flagellins.

Authors:  Kathleen K Shanks; Wei Guang; K Chul Kim; Erik P Lillehoj
Journal:  Clin Vaccine Immunol       Date:  2010-06-30

6.  Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis.

Authors:  I M Balfour-Lynn; N J Klein; R Dinwiddie
Journal:  Arch Dis Child       Date:  1997-08       Impact factor: 3.791

Review 7.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

8.  The tyrosine kinase BceF and the phosphotyrosine phosphatase BceD of Burkholderia contaminans are required for efficient invasion and epithelial disruption of a cystic fibrosis lung epithelial cell line.

Authors:  Ana S Ferreira; Inês N Silva; Fábio Fernandes; Ruth Pilkington; Máire Callaghan; Siobhán McClean; Leonilde M Moreira
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

Review 9.  New perspectives in understanding and management of the respiratory disease in cystic fibrosis.

Authors:  S Suter
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

10.  Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8.

Authors:  E DiMango; H J Zar; R Bryan; A Prince
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.